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A B S T R A C T
Background
Serum monoclonal anti-myelin-associated glycoprotein (anti-MAG) antibodies may be pathogenic in some people with immunoglob-
ulin M (IgM) paraprotein and demyelinating neuropathy. Immunotherapies aimed at reducing the level of these antibodies might be
expected to be beneficial. This is an update of a review first published in 2003 and previously updated in 2006 and 2012.
Objectives
To assess the effects of immunotherapy for IgM anti-MAG paraprotein-associated demyelinating peripheral neuropathy.
Search methods
On 1 February 2016 we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, and Embase for randomised controlled trials (RCTs). We also checked trials registers and bibliographies,
and contacted authors and experts in the field.
Selection criteria
We included randomised controlled trials (RCTs) or quasi-RCTs involving participants of any age treated with any type of immunother-
apy for anti-MAG antibody-associated demyelinating peripheral neuropathy with monoclonal gammopathy of undetermined signifi-
cance and of any severity.
Our primary outcome measures were numbers of participants improved in disability assessed with either or both of the Neuropathy
Impairment Scale (NIS) or the modified Rankin Scale (mRS) at six months after randomisation. Secondary outcome measures were:
mean improvement in disability, assessed with either the NIS or the mRS, 12 months after randomisation; change in impairment as
measured by improvement in the 10-metre walk time, change in a validated linear disability measure such as the Rasch-built Overall
Disability Scale (R-ODS) at six and 12 months after randomisation, change in subjective clinical scores and electrophysiological
parameters at six and 12 months after randomisation; change in serum IgM paraprotein concentration or anti-MAG antibody titre at
six months after randomisation; and adverse effects of treatments.
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Data collection and analysis
We followed standard methodological procedures expected by Cochrane.
Main results
We identified eight eligible trials (236 participants), which tested intravenous immunoglobulin (IVIg), interferon alfa-2a, plasma
exchange, cyclophosphamide and steroids, and rituximab. Two trials of IVIg (22 and 11 participants, including 20 with antibodies
against MAG), had comparable interventions and outcomes, but both were short-term trials. We also included two trials of rituximab
with comparable interventions and outcomes.
There were very few clinical or statistically significant benefits of the treatments used on the outcomes predefined for this review, but
not all the predefined outcomes were used in every included trial and more responsive outcomes are being developed. A well-performed
trial of IVIg, which was at low risk of bias, showed a statistical benefit in terms of improvement in mRS at two weeks and 10-metre
walk time at four weeks, but these short-term outcomes are of questionable clinical significance. Cyclophosphamide failed to show any
benefit in the single trial’s primary outcome, and showed a barely significant benefit in the primary outcome specified here, but some
toxic adverse events were identified.
Two trials of rituximab (80 participants) have been published, one of which (26 participants) was at high risk of bias. In the meta-
analysis, although the data are of low quality, rituximab is beneficial in improving disability scales (Inflammatory Neuropathy Cause and
Treatment (INCAT) improved at eight to 12 months (risk ratio (RR) 3.51, 95% confidence interval (CI) 1.30 to 9.45; 73 participants))
and significantly more participants improve in the global impression of change score (RR 1.86, 95% CI 1.27 to 2.71; 70 participants).
Other measures did not improve significantly, but wide CIs do not preclude some effect. Reported adverse effects of rituximab were
few, and mostly minor.
There were few serious adverse events in the other trials.
Authors’ conclusions
There is inadequate reliable evidence from trials of immunotherapies in anti-MAG paraproteinaemic neuropathy to form an evidence
base supporting any particular immunotherapy treatment. IVIg has a statistically but probably not clinically significant benefit in the
short term. The meta-analysis of two trials of rituximab provides, however, low-quality evidence of a benefit from this agent. The
conclusions of this meta-analysis await confirmation, as one of the two included studies is of very low quality. We require large well-
designed randomised trials of at least 12 months’ duration to assess existing or novel therapies, preferably employing unified, consistent,
well-designed, responsive, and valid outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Immune treatments for peripheral neuropathy caused by an IgM paraprotein antibody, which may bind to MAG, a protein on
the myelin sheath of nerves
Review question
What are the benefits and harms of immune treatments for peripheral neuropathy caused by an IgM paraprotein antibody that may
bind to myelin-associated glycoprotein (MAG)?
Background
There are several types of antibodies in the human body. They are more or less specifically adapted to recognise a target, usually a
’foreign’ protein such as a bit of a bacterium, virus or tumour. In some people too much of one type of antibody is made, called a
paraprotein. Some of these paraproteins are of the IgM class (IgM antibodies are usually an ’early attack force’ type of antibody). Some
of these antibodies may react against myelin-associated glycoprotein, also known as MAG.MAG is a molecule on the insulating myelin
sheath of nerves. The antibody probably results in damage to the nerve myelin to which it is bound and thus causes a specific type
of damage to the nerves, known as a peripheral neuropathy. Anti-MAG paraprotein-associated peripheral neuropathy is a condition
affecting more men than women, most commonly over the age of 60 years. It causes progressive sensory symptoms, unsteadiness and
tremor, and sometimes some weakness of the feet and lower legs.
Treatments that act on the immune system such as plasma exchange (which removes circulating antibodies and replaces blood plasma
with a clean plasma substitute), intravenous immunoglobulin (IVIg; antibodies that have been purified from donated blood), rituximab
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(which kills some of the cells that produce the antibody), corticosteroids, or anticancer drugs might be expected to reduce levels of
these neuropathy-causing IgM antibodies and slow or prevent progression of the disease.
Study characteristics
Many of these therapies have been tried in non-randomised studies, but we found only eight small randomised controlled trials (RCTs),
involving 236 participants, that met our criteria for inclusion.
Results and quality of the evidence
Two trials with 22 and 11 participants (20 with antibodies against MAG) suggest that IVIg may sometimes produce short-term
measurable benefit and is relatively safe, but the benefit is of doubtful clinical significance. No severe adverse effects related to IVIg were
reported in these trials. A trial of cyclophosphamide and corticosteroids showed somemild benefit. Two trials of rituximab demonstrated
a positive benefit of rituximab, but this evidence was of low quality because of small numbers of participants and concerns about the
design of one of the two studies. Reported adverse effects of rituximab were few, and mostly minor. Other trials did not allow us to
draw conclusions about the efficacy of other agents and reported few serious adverse events. We need large, well-designed RCTs to
assess the efficacy of the existing and new therapies, and better ways for doctors and researchers to detect changes that people report in
response to treatments.
The evidence is up to date to February 2016.
3Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Should rituximab versus placebo be used for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies?
Patient or population: people with IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
Setting: hospital and outpat ient treatment centres
Intervention: rituximab
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with rituximab
Number of participants
improved in disability
Assessed with: INCAT
score or INCAT Leg Dis-
ability Score
Follow-up: range 8 to 12
months1
Study population RR 3.51
(1.30 to 9.45)
73
(2 RCTs)
⊕⊕©©
low2
Stat ist ically signif icant
ef fect in meta-analysis
74 per 1000 260 per 1000
(96 to 700)
M ean improvement in
disability
Assessed with: INCAT
score or INCAT leg dis-
ability score
Scale f rom: 0 to 12 in
INCAT and 0 to 7 in IN-
CAT leg disability.
Follow-up: range 8 to 12
months1
The mean improvement
in INCAT score (see
text) at 8 to 12 months
was -0.18
The mean improve-
ment in INCAT score
(see text) at 8 to 12
months in the interven-
t ion group was 0.45
lower (0.85 lower to 0.
05 lower)
- 73
(2 RCTs)
⊕⊕©©
low2
Stat ist ically signif icant
improvement versus
placebo but probably
less than MCID
Improvement in 10-
metre walk time at 8 to
12 months1
The mean improvement
in 10-metre walk t ime
at 8 to 12 months was
0.14 seconds
The mean improvement
in 10-metre walk t ime
at 8 to 12 months in the
intervent ion group was
0.35 seconds more (1.
- 68
(2 RCTs)
⊕⊕⊕©
moderate4
MCID for 10-metre walk
approximately 0.4 sec-
onds. Borders on clin-
ically signif icant im-
provement,but wide CIs
4
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89 more to 1.19 less)
Participant subjective
impression of change
stable or improved at 8
to 12 months
Assessed with: VAS
f rom: 0 to 10
Follow-up: mean 8
months1
Study population RR 1.86
(1.27 to 2.71)
70
(2 RCTs)
⊕⊕©©
low3
Patient global impres-
sion of change im-
proved sim ilarly in both
studies in a t ime-depen-
dent manner (see data
tables)
447 per 1000 832 per 1000
(568 to 1000)
Change in serum IgM
paraprotein concentra-
tion 8 months after
treatment1
The mean change in
IgM level 8 months af -
ter treatment was 32.3
mg/ L
The mean change in
IgM level 8 months af ter
treatment in the inter-
vent ion group was 287.
7 mg/ L lower (328.98
lower to 244.42 lower)
- 26
(1 RCT)
⊕⊕⊕©
moderate4
An unsurprising reduc-
t ion in IgM in the ritux-
imab-treated group
Any adverse event Study population RR 1.18
(0.84 to 1.66)
80
(2 RCTs)
⊕©©©
very low5
No stat ist ically signif i-
cant dif f erence in ad-
verse ef fects. Serious
adverse ef fects too few
to make comment. Con-
sistency of adverse
event collect ion always
suspect
561 per 1000 662 per 1000
(471 to 931)
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; IgM : immunoglobulin M; INCAT score: Inf lammatory Neuropathy Cause and Treatment score;M CID: minimum clinically important dif f erence; RR: risk
rat io; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1The outcomes in the rituximab study were recorded at between 8 and 12 months, which is rat ional for the treatment of a
disease with rituximab. Thus we have reported this interval for this intervent ion (see text).
2Downgraded twice for imprecision (small underpowered studies) and unresponsive outcome measures.
3Downgraded twice for imprecision (small underpowered studies) and indirectness (pat ient impression of change).
4Downgraded once for imprecision (small underpowered studies).
5Downgraded three t imes for imprecision (small studies and small even numbers), trial design and inconsistent adverse event
recording.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Up to 10% of people with a peripheral neuropathy which is not
secondary to another primary illness have a paraprotein in the
serum (Kelly 1981). A paraprotein is an abnormal protein pro-
duced by bone marrow cells and may belong to one of the three
classes of immunoglobulin (Ig), IgG, IgA or IgM. The majority
of paraproteins in people with peripheral neuropathy are IgM,
produced by an initially benign condition of blood cells called
monoclonal gammopathy of undetermined significance (MGUS).
Of this group of paraproteins, 50% react with the CD57/HNK-
1 carbohydrate epitope found on myelin-associated glycoprotein
(MAG). This epitope is also found on other peripheral nerve
myelin molecules (myelin protein zero, peripheral myelin protein
22, sulphated glucuronyl paragloboside (SGPG), sulphated glu-
curonyl lactosaminyl paragloboside (SGLPG) and others) but the
antibodies are commonly referred to as anti-MAG.
Description of the condition
The clinical neuropathy associated with anti-MAG antibodies is
usually relatively phenotypically homogeneous, and consists of a
slowly progressive distal sensorimotor neuropathy with a variable
degree of ataxia and prominent tremor (Chassande 1998; Smith
1983; Smith 1987; Yeung 1991). The neurophysiological features
are demyelination, characteristically with more slowing of con-
duction in the distal than the proximal nerve segments (Kaku
1994). The term anti-MAG IgM paraproteinaemic demyelinat-
ing peripheral neuropathy (PDPN) is therefore sometimes used to
refer to this condition.
Other antibody reactivities exist in people with neuropathy and
an IgM paraprotein and they have tentatively been classified into
small homogeneous groupings. Examples include motor neu-
ropathies with anti-GM1 antibodies (Steck 1996), chronic sensory
ataxic neuropathy associated with antibodies to GQ1b and other
gangliosideswith at least two sialic acid groups calledCANOMAD
(Willison 2001), and sensory demyelinating neuropathies with
anti-sulfatide antibodies (Ferrari 1998). However, the most clearly
described, relatively homogeneous group remains the neuropathy
associated with IgM anti-MAG antibodies, the subject of this re-
view.
Considerable evidence exists that anti-MAG antibodies are
pathogenic. Deposits of the IgM paraprotein have been demon-
strated in sural nerves of affected people (Takatsu 1985). The
paraprotein is bound to myelin in a similar distribution to MAG.
In some cases the binding has been associated with the deposi-
tion of activated complement components (Hays 1988; Monaco
1990). Demyelination has also been induced in some animal
models by the passive transfer of anti-MAG antibodies (Tatum
1993; Willison 1988), and more recently by immunisation with
SGPG (Ilyas 2008). People have been reported to respond to im-
munotherapies, the improvement sometimes correlating with a
reduction in levels of IgM (Wilson 1999).
Description of the intervention
There are a number of possible therapies which have been
described as effective in the treatment of anti-MAG parapro-
teinaemic neuropathy, includingplasma exchange, corticosteroids,
intravenous immunoglobulin (IVIg), cyclophosphamide, fludara-
bine and cytarabine, chlorambucil, alpha-interferon, rituximab or
combinations of these agents. These are described below in the
Results and Discussion sections.
Currently, treatment is largely decided on the informed choice of
the individual. Many people are too old or too mildly affected
to make the risks of treatment worthwhile. There are only eight
randomised controlled trials (RCTs) testing the efficacy of the var-
ious immunosuppressive regimens in IgM paraproteinaemic neu-
ropathies (Comi 2002; Dalakas 1996; Dalakas 2009; Dyck 1991;
Léger 2013; Mariette 1997; Mariette 2000; Niermeijer 2007;
Oksenhendler 1995). Most case series have been small, included
diverse groups of participants and have not presented results of
efficacy clearly.
How the intervention might work
Treatment strategies have either aimed to reduce the IgM para-
protein concentration, by removing the antibody or targeting the
presumed monoclonal B-cell clone and reducing its production,
or to interfere with the presumed effector mechanisms such as
complement activation or macrophage recruitment.
O B J E C T I V E S
To assess the effects of immunotherapy for IgM anti-MAG para-
protein-associated demyelinating peripheral neuropathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and quasi-RCTs using any immunotherapy in
anti-MAG paraproteinaemic demyelinating peripheral neuropa-
thy (PDPN).
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Types of participants
We includedparticipants of any agewith a diagnosis ofMGUS, de-
myelinating neuropathy and anti-MAG antibodies. Other causes
of peripheral neuropathy should have been ruled out.
Paraproteins were to be of the IgM class and shown to be reactive
with MAG or SGPG by a validated method which could be:
• western blotting against human sciatic nerve homogenate;
• enzyme-linked immunosorbent assay (ELISA) for MAG or
SGPG or SGLPG;
• complement fixation test against human sciatic nerve
homogenate (confirmed by a second method);
• thin layer chromatographic immuno-overlay against SGPG
or SGLPG.
As anti-MAG methods varied, we accepted positive anti-MAG
results as reported by the trial authors and we did not define a
threshold titre for positivity.
The neuropathy was to be typical distal symmetrical sensory
or sensorimotor and should fit published criteria for slowing of
motor nerve conduction in chronic inflammatory demyelinating
polyradiculoneuropathy (Ad Hoc 1991 or Nicolas 2002), with or
without prominent slowing in distal nerve segments. The occur-
rence of conduction block in this neuropathy is debated and was
not an exclusion criterion.
We included studies that did not exactly fulfil these criteria, if
necessary after consultation with the original study authors, pro-
vided the review authors agreed that IgM anti-MAG-associated
demyelinating neuropathy was the preferred diagnosis. We noted
any departure from the diagnostic criteria.
Types of interventions
We included any type of immunotherapy used for the treatment
of IgM paraprotein-associated demyelinating peripheral neuropa-
thy with anti-MAG antibodies. We considered the following ther-
apies for inclusion: plasmapheresis or plasma exchange or se-
lective apheresis, intravenous immunoglobulin (IVIg), corticos-
teroids (prednisolone, prednisone, methylprednisolone, dexam-
ethasone), chlorambucil, cyclophosphamide, azathioprine, flu-
darabine,cladribine, interferon alfa-2a, adriamycin, melphalan,
and monoclonal antibody-based therapies (for example, ritux-
imab). We considered comparisons versus placebo, another treat-
ment, or an alternative dosage or treatment protocol. Therapies
could be administered using any protocol (for example, single
agent, combined therapy or sequential administration). If the con-
trol arm received a co-intervention then the experimental arm had
to also receive that same treatment.
Types of outcome measures
Primary outcomes
Predefined primary outcome measures were numbers of partic-
ipants improved in disability at six months after randomisation
assessed with either or both of:
(a) the Neuropathy Impairment Scale (NIS) (Dyck 1980; Dyck
2005) by at least 10% (maximum score 244);
(b) the modified Rankin Scale (mRS) (Bamford 1989) (scale 0 to
6).
We selected the NIS and mRS as primary outcome measures, as
we considered them to be broad, commonly-used scores that were
potentially easy to retrospectively derive from collected data. We
predefined six months as the favoured time point for re-evaluation
on the basis that IgM anti-MAG paraprotein-associated neuropa-
thy is a chronic and slowly progressive disorder. A reduction in
either score indicates improvement and as there is no published
minimum clinically important difference for the NIS, we defined
a 10% change as improvement.
Secondary outcomes
Secondary outcome measures were:
1. mean improvement in disability assessed with either the
NIS or the mRS, or both, 12 months after randomisation;
2. change in impairment as measured by improvement in 10-
metre walk time six and 12 months after randomisation
(improvement is reduction in walk time);
3. change in a validated linear disability measure such as the
Rasch-built Overall Disability Scale (R-ODS) at six and 12
months after randomisation;
4. change in subjective clinical scores at six and 12 months
after randomisation;
5. change in electrophysiological measures:
i) reappearance of sural sensory nerve action potentials
(SNAPs) or compound muscle action potentials (CMAPs) in
previously inexcitable nerves, or
ii) electrophysiological change in at least two nerves
(where improvement was defined as more than a 20% increase in
motor or sensory nerve conduction velocities or more than a
20% decrease in motor distal latencies) compared to baseline at
six and 12 months after randomisation;
6. change in serum IgM paraprotein concentration or anti-
MAG titre (significant improvement defined as at least a 20%
reduction in IgM or a 50% reduction of anti-MAG titre
compared to baseline at six months after randomisation);
7. adverse effects from treatment during the trial period,
graded as:
◦ minor - not requiring action;
◦ moderate - requiring alteration in dosage, drug
regimen or other intervention; or
◦ severe - requiring withdrawal from study or resulting
in hospitalisation or death.
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Search methods for identification of studies
We searched the Cochrane Neuromuscular Specialised Register (1
February 2016), the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (2016, Issue 1 in the Cochrane Library), MED-
LINE (January 1966 to January 2016) and Embase (January 1980
to January 2016) for randomised controlled trials. We reviewed
bibliographies to identify other controlled trials. We contacted
trial authors and experts in the field to identify additional pub-
lished or unpublished data.
We also searched ClinicalTrials.gov (ClinicalTrials.gov) and the
World Health Organization International Clinical trials Registry
Platform (ICTRP) (www.who.int/ictrp/en/), on23October 2014.
The detailed search strategies are in the appendices: MEDLINE
(Appendix 1), Embase (Appendix 2), CENTRAL (Appendix 3)
and Cochrane Neuromuscular Specialised Register (Appendix 4).
We searched clinical trials registries from within their search en-
gines with the terms “myelin associated glycoprotein”, “anti-MAG
neuropathy” and “paraproteinaemic neuropathy” (Appendix 5).
Data collection and analysis
Selection of studies
Two review authors independently checked titles and abstracts
identified from database searches and bibliographies. Both review
authors obtained and assessed the full text of all potentially rele-
vant studies. Both review authors decided which trials fitted the
inclusion criteria, resolving disagreements about inclusion by dis-
cussion.
Data extraction and management
Both review authors independently performed data extraction
onto a custom-designed data extraction sheet, cross-checked the
data and resolved differences by discussion. We requested and ob-
tained missing data from the trial authors whenever possible.
Assessment of risk of bias in included studies
The review authors assessed the risk of bias in included studies
using the methods described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). They considered:
sequence generation; allocation concealment; blinding of partici-
pants, personnel and outcome assessors; incomplete outcome data;
selective outcome reporting; and other potential sources of bias.
We graded these items as at low risk of bias, high risk of bias or
unclear. Each review author graded the risk of bias independently;
we then compared the results and reached agreement about dif-
ferences by consensus.
Data synthesis
Wepooled trial outcomes for interventions when possible. We cal-
culated a weighted treatment effect across trials (using a fixed-ef-
fectmodel) with theCochrane statistical package ReviewManager
5 (RevMan 2014). We expressed results as risk ratios (RRs) with
95% confidence intervals (CIs) for dichotomous outcomes, and
mean differences (MDs) with 95% CIs for continuous outcomes.
We tried to analyse all the primary and secondary outcomes under
consideration. Because very little meta-analysis was possible, we
did not perform sensitivity analysis. We did not plan any subgroup
analyses.
‘Summary of findings’ tables
We included ’Summary of findings’ tables where it was possible to
populate these with meaningful data. Where possible, we reported
all outcomes at six months after randomisation:
1. number of participants improved in disability assessed with
either or both of the NIS and the mRS;
2. mean improvement in disability assessed with either the
NIS or the mRS;
3. change in impairment as measured by improvement in 10-
metre walk time;
4. change in subjective clinical scores (participant subjective
impression of change stable or improved);
5. change in serum IgM paraprotein concentration; and
6. any adverse event.
R E S U L T S
Description of studies
Results of the search
Up to 2006, a search of the Cochrane Neuromuscular Specialised
Register revealed 12 possible trials. Searching MEDLINE and
Embase with the same strategy and handsearching bibliographies
failed to reveal further trials. A further search to July 2009 for
the update identified trials and papers as follows: CENTRAL: 4,
MEDLINE: 679 (13 papers reviewed), and Embase: 212 (seven
reviewed). Review of the full texts identified two new eligible stud-
ies (Dalakas 2009;Niermeijer 2007). A further search for the 2012
update identified the following numbers of papers: CochraneNeu-
romuscular Specialised Register: 3, CENTRAL: 52, MEDLINE:
116, and Embase: 317, with no new trials identified. In 2015,
searches identified the following numbers of papers: Cochrane
Neuromuscular Specialised Register: 27 papers, CENTRAL: 76
papers,MEDLINE: 65 newpapers (1035 total), Embase: 112 new
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papers (1645 total). A search of the Database of Abstracts of Re-
views of Effectiveness (DARE) identified four papers and searches
of ClinicalTrials.gov and ICTRP (www.who.int/ictrp/en/) identi-
fied three each (identified from the resources above).
Figure 1 presents a flow chart of the study selection process for
this update.
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Figure 1. PRISMA chart for searched to included studies of IgM paraproteinaemic neuropathy
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Included studies
The eight included studies enrolled 236 participants (see
Characteristics of included studies; Figure 1), of whom 104 were
treated at some stage with the study intervention. In only three
trials were all the predeclared inclusion criteria met (Comi 2002;
Dalakas 2009; Niermeijer 2007). Three studies stated that the
participants had benign monoclonal gammopathy or monoclonal
gammopathy of undetermined significance (Comi 2002; Dalakas
2009; Niermeijer 2007). Other studies may have included partic-
ipants with Waldenstrom’s macroglobulinaemia (Mariette 1997;
Mariette 2000; Oksenhendler 1995), or participants with other
causes of neuropathy (Dalakas 1996). Three studies stated that
all participants had a demyelinating neuropathy (Comi 2002;
Dalakas 1996; Dalakas 2009), but only one of these stipulated the
electrophysiological criteria for demyelination used (Comi 2002).
All of the included participants had serum IgM anti-MAG activ-
ity tested but this was established by various methods of western
blotting, immunofluorescence or anti-SGPG ELISA testing. In
total, 194 of 236 participants had anti-MAG activity, and in four
of eight studies all the participants in the study had anti-MAG ac-
tivity (Dalakas 2009; Léger 2013; Mariette 1997; Mariette 2000).
Niermeijer 2007 stated that numbers of participantswere too small
to establish an effect of anti-MAG antibodies and no original data
were available to analyse the subgroup of anti-MAG participants
in the other three studies.
The interventions and trial designs of the eight included studies
werewidely different. Two studies compared IVIgwith placebo in a
placebo-controlled cross-over design (Comi 2002; Dalakas 1996).
Both of these studies included a one-month minimum washout
period between the cross-over arms, considered rather short given
the half-life of IgG, even though Comi 2002 gave a single dose
of IVIg compared to the three monthly doses in Dalakas 1996.
One study compared interferon alfa-2a with IVIg in an open-la-
bel design (Mariette 1997) and another with placebo in a double-
blind design (Mariette 2000). One study compared chlorambucil
alone with a combination of chlorambucil and plasma exchange
(Oksenhendler 1995). The most recent trials studied the effect of
cyclophosphamide and prednisolone (Niermeijer 2007), or ritux-
imab (Dalakas 2009; Léger 2013). We included all eight studies,
despite the lack of fulfilment of all inclusion criteria by five of
them.
Excluded studies
We excluded 19 studies that had been considered at the title se-
lection stage (see Excluded studies). Of these, we excluded one
trial as serum IgM anti-MAG activity was not tested in the 21
participants with IgM-associated neuropathy and specific criteria
for demyelinating neuropathies were not an entry criterion (Dyck
1991). We excluded two rituximab trials: as one (with seven par-
ticipants) was open (Renaud 2003), the other (including nine par-
ticipants) had a non-randomised control group and unblinded as-
sessments (Pestronk 2003). Other reasons for excluding studies
are shown in Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2 for a summary of the review authors’ ’Risk of bias’
assessments for the included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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All the included trials had a randomised design and participants
were randomly assigned to receive the intervention or control
for the whole trial, or the first arm in cross-over studies (see
Characteristics of included studies). All but one of the studies stip-
ulated explicit diagnostic criteria (Dalakas 1996). Baseline char-
acteristics were not significantly different in six of the studies, but
in Dalakas 2009 the groups were very unbalanced with very few
men in the rituximab-treated group at randomisation. Differences
in baseline characteristics were also present in Dalakas 1996.
The trials of IVIg both had low risk of bias (Comi 2002; Dalakas
1996). In Dalakas 1996, the risk of bias was a little greater, as allo-
cation concealment was unclear and the participants randomised
to placebo were much older than in the IVIg arm, although this
did not reach significance with the nine anti-MAG participants
included. However, the sensory scores were significantly higher in
the placebo group than the IVIg-treated group. Furthermore, this
study did not state explicit diagnostic criteria. Both trials suffer
from a short washout period and a potential carry-over effect, al-
though this would be expected to reduce the significance of any
therapeutic effect of IVIg.
Mariette et al studied interferon alfa-2a in two studies (Mariette
1997; Mariette 2000). The second study was blinded and con-
trolled and at a much lower risk of bias than the preliminary ran-
domised open trial. Four of 10 participants in the IVIg group in
Mariette 1997 and three of 12 in the interferon group in Mariette
2000 dropped out early in the trial, which may confound results
in these small groups.
Oksenhendler 1995 studied plasma exchange plus chlorambucil
versus chlorambucil alone. As a result of the plasma exchange pro-
cedure, the blinding and allocation concealment were inadequate.
Furthermore, although dropouts were balanced in the two groups
(four of 22 in one group and four of 23 in the other), and the in-
vestigators performed an intention-to-treat analysis, the dropout
numbers were deemed significant given the small number of in-
cluded participants.Overall, we judged the risk of bias in this small
study to be high.
The first published RCT of rituximab for paraproteinaemic de-
myelinating peripheral neuropathy (PDPN) was at high overall
risk of bias (Dalakas 2009). The treatment groups at entry were
unbalanced with respect to sex distribution (PDPN affects more
men than women, but only two of 13 participants randomised to
treatment were men). The randomisation method was not clear,
and although the National Institutes of Health (NIH) pharmacy
provided drug and placebo, it is not clear that the trial maintained
allocation concealment. Most importantly, one participant was
randomised and then removed from the trial having received rit-
uximab and suffered an adverse event; this participant’s data were
not analysed. A further participant was removed at the analysis
stage when it became clear the person did not fulfil the inclusion
criteria; statistical analyses were done including and excluding this
participant. We judged a second trial of rituximab to be at low risk
of bias. The trial was entered in ClinicalTrials.gov, but the pub-
lished protocol does not contain all outcomes presented in the trial
report, which appear to have been added post protocol publica-
tion. To clarify the meta-analysis, we requested trial data from the
authors of these two studies. Data were provided for Léger 2013.
The authors of Dalakas 2009 were unable to provide any outcome
data for their trial, which were lost with a retiring colleague.
We considered the study of cyclophosphamide and steroid to be
at low risk of bias in all domains (Niermeijer 2007). We analysed
the first six months of the trial, as after this point participants who
experienced a clinical decline were rerandomised to treatmentwith
a different corticosteroid or cyclophosphamide.
Effects of interventions
See: Summary of findings for the main comparison
Rituximab versus placebo for treating IgM anti-myelin-associated
glycoprotein paraprotein-associated peripheral neuropathy
General comment
Two trials compared IVIg with placebo (Comi 2002; Dalakas
1996). Their designs differed in IVIg dose and outcome measures
and neither provided six- or 12-month assessments.
Two trials tested rituximab in a very similar group of participants,
using fairly similar outcomes. In Dalakas 2009, 26 participants
were randomised to rituximab or a placebo infusion. There were
concerns about the validity of the statistical manipulations used
in this trial (see above and below) and corroborative data were not
available. Léger 2013 also studied rituximab and randomised 54
participants to rituximab or placebo. The study produced similar
results to Dalakas 2009 (see analysis below). The trial data were
analysed at slightly different time points, but the review authors
considered eight- and 12- month outcomes similar enough in this
slowly changing disease.
The other four trials tested different interventions or combinations
of treatment.Oksenhendler 1995 comparedplasma exchangewith
no plasma exchange in participants receiving chlorambucil. Mari-
ette et al compared IVIg with interferon alfa-2a (Mariette 1997),
and, in a follow-up study, interferon alfa-2awith placebo (Mariette
2000). Niermeijer 2007 randomised participants to cyclophos-
phamide and prednisolone pulses or placebo in a six-month-long
phase one of a 24-month trial. To satisfy ethical concerns, any
participant who deteriorated in phase one was reassigned to cy-
clophosphamide and prednisolone (if they had received placebo
in phase one) or dexamethasone (if they had received cyclophos-
phamide and prednisolone) (termed phase 2 of the study), mak-
ing the 24-month outcomes difficult to assess. In phase two the
placebo group was not truly randomised, as phase two contained
only participants who had not improved on placebo, nine of 19
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participants having switched to active treatment in phase two. Af-
ter discussion of the trial data released by the trial authors, we did
not include six-month to 24-month outcomes in the analysis.
The primary and secondary outcome measures used in all these
trials varied widely and those predefined for this review were rarely
provided.
Intravenous immunoglobulin versus placebo
Investigated in Comi 2002 and Dalakas 1996. See ’Summary of
findings’ (Additional Table 1).
Primary outcome measures
One trial with 22 participants (Comi 2002), of IVIg versus
placebo in IgM paraprotein-associated neuropathy used the mod-
ified Rankin Scale (mRS). However, this was a short trial and
the investigators only measured the primary outcome at two and
four weeks, not at six months. Eleven of 22 participants had anti-
MAG antibodies but the data concerning the anti-MAG partici-
pant subgroup were not available. At two weeks, the mRS score
showed a significant improvement with IVIg (-0.38, standard de-
viation (SD) 0.58) over placebo (+0.19, SD 0.51) at two weeks
(P = 0.008), a difference that may not be clinically significant.
No significant difference between the groups was present at four
weeks.
The primary outcome of Comi 2002 was the Inflammatory Neu-
ropathy Cause and Treatment (INCAT) disability score at four
weeks. This was not one of our prespecified outcomemeasures (see
Discussion). After two weeks, the INCAT disability score did not
change significantly; there was no difference between the groups
and no evidence of a carry-over effect. After four weeks, the IN-
CAT disability score decreased by a mean of 0.55 (SD 0.67) grades
in the IVIg period (P = 0.001), with no significant change (mean
0.05 (SD 0.90)) in the placebo period. Only the mean difference
(MD) between the treatment effects in the two four-week periods
was significant (0.5 of a grade, 95% confidence interval (CI) 0.00
to 1.00).
Secondary outcome measures
The secondary outcomes at time points selected for this review
were not available because the trials were both so short.
Related secondary outcomes were measured at different time
points (two and four weeks) and the results were presented as MD
between treatments.
a. One trial assessed the 10-metre walk (Comi 2002), but only at
four weeks in the first arm of the study, as there was significant
evidence of a carry-over effect into the second arm. There was a
significant reduction in 10-metre walk time with IVIg compared
with placebo in the whole IgM treatment group (MD 2.77 sec-
onds, 95% CI 0.01 to 5.54). No data were available on the anti-
MAG participants alone, but the trial authors state that MAG an-
tibodies “did not influence the response to IVIg treatment”.
b. Serum data: not enough information was available on anti-
MAG titres or serum IgMconcentrations inDalakas 1996 tomake
a meaningful comment.
No 12-month outcomes were available.
Adverse events
Two studies compared IVIg and placebo (Comi 2002; Dalakas
1996), but data for the anti-MAG subgroup were not available.
In Comi 2002, one participant had an aseptic meningitis and a
rash after IVIg treatment. It is not clear whether she completed
the three-month trial period. Two moderate adverse events oc-
curred in the placebo treatment arm in Comi 2002, one retinal
vein thrombosis and one episode of transient diplopia. In Dalakas
1996, no serious adverse events occurred as a result of IVIg infu-
sion, but mild and transient effects were “more common in the
IVIg than the placebo group”. No further analysis was possible.
For adverse events of IVIg in the interferon alfa-2a versus IVIg
trial (Mariette 1997), see below.
Interferon alfa-2a versus placebo or IVIg
Investigated in Mariette 1997 and Mariette 2000.
Primary outcome measures
The mRS was not assessed. The Neuropathy Impairment Scale
(NIS) was the primary outcome in both studies involving inter-
feron alfa-2a (referred to as the Clinical Neuropathy Disability
Score (CNDS), a scale derived with minor modifications from the
NIS, maximum score 93 (higher scores indicate greater disabil-
ity)). In the initial randomised but open parallel-group study of
interferon alfa-2a versus IVIg (Mariette 1997), participants in the
IVIg group worsened by amean of 2.3 (SD 7.6) points on theNIS
at six months, and those in the interferon alfa-2a group improved
by 7.5 (11.1) points, aMD of 9.80 (95%CI 1.46 to 18.14, n = 20)
in favour of interferon alfa-2a (Analysis 1.1). However, Mariette
2000 (n = 24), a randomised and blinded trial of interferon alfa-2a
versus placebo at low risk of bias, failed to confirm the beneficial
effect of interferon alfa-2a in the primary outcome at six months
(Analysis 2.1).
Secondary outcome measures
Neither trial assessed the 10-metre walk at any time point.
The two trials derived a subjective clinical score (Mariette 1997;
Mariette 2000). In the unblinded 1997 study, the subjective scores
improved significantly in favour of interferon alfa-2a over IVIg
(MD 3.10, 95% CI 1.02 to 5.18, n = 20; Analysis 1.2). In the
later blinded and reported ’negative’ placebo-controlled study of
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interferon alfa-2a, the subjective scores were not presented in the
published data.
The presence of sural sensory nerve action potentials (SNAPs) was
examined at six months in both studies. The number of partic-
ipants with detectable sural nerve SNAPs did not improve with
either interferon alfa-2a or IVIg in the first study and exhibited
“no significant improvement” in the second (data not presented).
More participants had recordable median SNAPs after six months
treatment with interferon alfa-2a (2/7 improved to 5/7) compared
to IVIg (4/8 declined to 1/8) in the first study (Mariette 1997).
In Mariette 1997, IgM paraprotein bands and anti-MAG activity
were still detectable at six months in all participants but only de-
creased significantly in two participants receiving interferon alfa-
2a (50% reduction each). No 12-month outcome data for serum
data were published.
Adverse events
In both interferon alfa-2a trials all included participants had anti-
MAG serum activity (Mariette 1997; Mariette 2000). Interferon
alfa-2a caused flu-like symptoms in all 10 participants in the open
study (Mariette 1997), which were persistent and required taper-
ing of the dose in three (moderate side effects). A further three par-
ticipants required dose-tapering for systemic adverse effects (also
moderate). One of 10 participants in the IVIg treatment group
withdrew because of self-limiting erythroderma (Mariette 1997).
No other mild or moderate side effects were reported with IVIg.
In the placebo-controlled, blinded study, two of 12 participants
withdrew from the study because of side effects (severe), one with
diarrhoea and one with flu-like symptoms (Mariette 2000). One
participant withdrew with worsening of neuropathy. There were
no other severe side effects reported for interferon alfa-2a.
Chlorambucil and plasma exchange versus
chlorambucil alone
Investigated in Oksenhendler 1995.
Primary outcome measures
In a comparison of chlorambucil and plasma exchange versus chlo-
rambucil alone in IgMparaprotein-associatedneuropathy, theNIS
at four months showed no statistically significant difference in
outcome (Oksenhendler 1995). The trialists assessed neither the
NIS nor the mRS at the six-month time point specified for this re-
view. Data were not available for the anti-MAG subgroup alone, as
participants with anti-MAG activity were not differentiated from
those without.
Secondary outcome measures
The change in NIS at 12 months was no different between the
plasma exchange plus chlorambucil and the chlorambucil-alone
groups.
The 10-metre walk time was not recorded at six months.
A subjective clinical score was not recorded at six months. There
was “no difference” in the subjective clinical score at 12 months
between the groups.
SNAPs were not recorded at six months.
IgMparaprotein concentrations and anti-MAG(anti-myelin IgM)
titres were determined prior to entry but no results were given
for later time points other than a comment in the paper that the
response was not associatedwith a significant decrease in the serum
IgM concentration.
Adverse events
In Oksenhendler 1995, there were no serious adverse events from
plasma exchange, but side effects of chlorambucil were common.
Ten of the 44 participants required temporary suspension or ta-
pering of the chlorambucil dosage because of haematotoxicity, but
none had to cease treatment.
Rituximab versus placebo
In 2012 only one study had been published using rituximab as
an intervention for paraproteinaemic neuropathy that fulfilled our
inclusion criteria (Dalakas 2009). A second study called RiMAG
has now been published and we include it here (Léger 2013). See
Summary of findings for the main comparison.
Dalakas 2009 randomised 26 participants to receive either ritux-
imab or placebo at a standard dose of four infusions of 375 mg/
m2 every week for four weeks. Outcomes were measured at eight
months (which for the purposes of this review we have used as
six-month outcomes). One randomised participant had a severe
anaphylactic adverse event with the first infusion of the drug. The
participant was replaced and not included in any further analysis.
One further participant randomised to rituximab and treated in
accord with the protocol was found to have had an INCAT leg
score at entry of zero (inadvertently assigned as 1 at entry). He
could not therefore have improved. We have performed the anal-
ysis here with the participant included as in the protocol for this
review.
Some discrepancies exist in the results in the published paper (see
below) (Dalakas 2009). These were resolved through enquiry with
the trial author.Original trial data were notmade available in 2012
and further requests in 2014 and 2015 were not fruitful. Trial data
were “entered directly by the statistician who retired more than 10
years ago” and he was untraceable.
Léger 2013 randomised 54 participants to receive either rituximab
in a standard 375 mg/m2 dose or placebo. Outcomes were mea-
sured at 0 and 12 months, but upon request, the trial authors
also made nine-month data available for the INCAT scale, change
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in INCAT scale and IgM levels, to correspond to outcomes of
Dalakas 2009. We requested data for the leg subscale of the IN-
CAT score but these were not available. The outcomes in the pub-
lished and amended ClinicalTrials.gov protocol are limited and
do not fully correspond to the outcomes in the methods section
of the published paper (which are those with results). There is no
suggestion of suppression of negative outcome data or selective
reporting, but these outcomes could have been decided post hoc.
Primary outcome measures
These two studies included neither the NIS nor the mRS as out-
comes. The INCAT leg score reported in Dalakas 2009 corre-
sponds broadly to the mRS and thus we used this in our analysis
both as a continuous and a dichotomous outcome. For the di-
chotomous improvement we have compared the leg score at eight
months from Dalakas 2009 with the dichotomous complete IN-
CAT score at 12 months from Léger 2013 (Analysis 3.1; Figure
3). The RR for improvement was 3.51, 95% CI 1.30 to 9.45 (I2 =
0%, 73 participants).Wewill perform a six-monthmeta-analysis if
other studies become available. Using the published eight-month
data from Dalakas 2009 and 12-month data from Léger 2013,
the mean improvement in the INCAT leg disability score (MD
-0.45, 95% CI -0.85 to -0.05; I2 = 0%) was statistically signifi-
cant, whether the INCAT 0-score participant from Dalakas 2009
was included in the analysis or not (Summary of findings for the
main comparison; Analysis 3.2). Participant-level data obtained
for nine-month improvement from Léger 2013 (not published),
which are at a more comparable time point to Dalakas 2009, give
a MD of -0.33, 95% CI -0.73 to 0.07 (I2 = 0%, 70 participants)
in the same direction as the longer time point but including the
possibility of no effect (Analysis 3.3).
Figure 3. Forest plot of comparison: 3 Rituximab versus placebo, outcome: 3.1 Number of participants
improved on INCAT score (see text) at 8-12 months.
(Note: in the published paper of Dalakas 2009 there is a discrep-
ancy between the data for the INCAT leg score in the text and in
the published table. We checked the data with the trial authors
who gave verbal clarification and we included the correct figures.
No recorded trial data were made available.)
Secondary outcome measures
Secondary outcomes that we could include in our analyses were the
10-metre walk time, the change in IgM levels, and anti-MAG titre,
but these were all measured at eight months in Dalakas 2009 and
at 12 months in Léger 2013. Nine-month data were not available
for Léger 2013 except for the IgM levels.
The 10-metre walk times did not improve significantly, either in
terms of time to walk (MD -0.35 seconds, 95% CI -1.89 to 1.19;
I2 = 0%, 68 participants) or numbers of participants improved
(RR 1.80, 95% CI 0.83 to 3.92; 26 participants; Dalakas 2009
only - data from Léger requested; Analysis 3.5; Analysis 3.6). As
might be expected, there was a measurable and significant decrease
in the level of serum IgM eight months after rituximab (reduction
of 286 mg/dL, 95% CI 329 to 244; 26 participants; Analysis 3.7).
Less expected (from reports of other studies of treatment of anti-
MAG neuropathy) but not surprising was a decrease in the titre of
anti-MAG activity of -17.79 units/mL (95% CI -33.33 to -2.25;
Analysis 3.8; I2 = 0%, 71 participants).
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Outcome measures not prespecified in this protocol
Both studies included participant “clinical assessments and ques-
tionnaires” (not further described). The RR for “stable or im-
proved” at eight to 12 months was 1.86 (95% CI 1.27 to 2.71; I2
= 0%, 70 participants) in favour of rituximab (Analysis 3.9). For
participants “improved” only at eight to 12 months, the RR was
9.67 with a wide CI (95% CI 1.84 to 50.85; I2 = 0%, 70 partic-
ipants) albeit statistically significant (Analysis 3.10). Léger 2013
presented results for the Short Form 36Health Survey (SF36) with
a MD improvement of 15.50 (95% CI 5.24 to 25.76; 37 partici-
pants) in the physical subscores (Analysis 3.11) but no statistically
significant change in the mental subscores (MD 6.60, 95% CI -
0.35 to 13.55; 41 participants; Analysis 3.12). These assessments
were not prespecified as primary or secondary outcomes.
Adverse events
There were not significantly more adverse events in the rituximab
group (RR 1.18, 95% CI 0.84 to 1.66; I2 = 0%, 80 participants;
Analysis 3.13). Most adverse events were minor, including mild
temperature increases and chills, headaches andmild hypotension,
nausea, vomiting, dizziness and lightheadedness, and rash. One
severe adverse event of bronchospasm led to the participant being
removed from Dalakas 2009, despite receiving the drug; his data
were not included in the published results. In Léger 2013, one
participant with rituximab was withdrawn from the study after
developing a bradycardia. The RR for severe adverse events was
3.11 (95% CI 0.34 to 28.54; I2 = 0%, 80 participants; Analysis
3.14), but this figure should be interpreted with caution, given the
small number of participants and single-integer events.
Cyclophosphamide and prednisolone combination
versus placebo
The only trial to use this combination as an intervention was
Niermeijer 2007. See ’Summary of findings’ Additional Table 2.
Values for outcomes in this study were presented as means and
95% CIs. We calculated SDs from the 95% CIs.
The trial authors made original trial data available and we con-
sidered whether to carry out further statistical analysis to use the
data after six months from phase two (see Effects of interventions
above). However, after discussion we did not consider the data to
be valid, as the re-allocation of participants was not truly random
and the results would therefore be significantly biased.
Primary outcome measures
The mRS at six months was included as one of the outcomes of
phase one of this trial, the only disability data that could be in-
cluded in this review. At six months a (barely) significant improve-
ment in the mean mRS was present, with a MD of -0.31 points
(95% CI -0.61 to -0.01; 34 participants; Analysis 4.1), with no
significant difference in the number of participants improved at six
months when we extracted the dichotomous data from the dataset
provided by the authors (3/16 improved with cyclophosphamide
and prednisolone combination versus 1/19with placebo, RR 3.56,
95% CI 0.41 to 30.99; 35 participants; Analysis 4.2.
Secondary outcome measures
The authors of this trial used the RivermeadMobility Index (RMI)
as their primary outcome measure. We included the RMI as a sec-
ondary outcome under subjective clinical scores. No significant
improvement in the RMI was present after six months of cyclo-
phosphamide and prednisolone (MD 0.42, 95%CI -0.41 to 1.25;
34 participants; Analysis 4.3).
Adverse events
Adverse events were not specifically sought in this trial. One par-
ticipant receiving cyclophosphamide withdrew because of angina
and was lost to follow-up, and one participant withdrew because
of rapid progression of neuropathy. A further participant, who was
also cyclophosphamide-treated,withdrewduring the seven-month
to 12-month phase. The trialists reported that nausea was signif-
icantly more common in the cyclophosphamide-treated group (P
= 0.001), but provided no further details.
Three of 35 participants (8.6%) who had received cyclophospha-
mide developed an immunocytoma not requiring further treat-
ment at five years of follow-up.
D I S C U S S I O N
Randomised controlled trials (RCTs)
We identified eightRCTs for this update. Four fulfilled all our strict
predefined inclusion criteria (Comi 2002; Dalakas 2009; Léger
2013; Niermeijer 2007). The trials of Comi, Leger and Niermeijer
had a low risk of bias, whereas Dalakas 2009 had a high risk of bias
in multiple domains (Figure 2). We included the four other RCTs
that did not fulfil all the inclusion criteria, because their inclusion
criteria closely approximated to those intended.
According to evidence from two trials, IVIg may produce some
short-term benefit in the treatment of anti-MAG IgM para-
proteinaemic neuropathy. One double-blind, placebo-controlled
study with minimal bias showed benefit of IVIg at four weeks in
one of the primary outcome measures (mRS) and the 10-metre
walk time secondary outcome measure but no other significant
outcomes (Comi 2002). The outcomes were available only at four
weeks and were not available for the predefined endpoints of six
and 12 months; it is not clear whether any short-term benefit
would be sustained or whether IVIg is clinically useful. Further-
more, this trial was of IgM paraproteinaemic neuropathy and not
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all the included participants had associated anti-MAG activity. Ev-
idence for any benefit from IVIg should be regarded with caution.
Two trials with interferon alfa-2a gave contradictory results. Inter-
feron alfa-2a appeared to be of benefit in treating anti-MAG neu-
ropathy when tested in an open trial with IVIg (Mariette 1997).
Because this trial was not blinded it was at high risk of bias. The
later, less biased, double-blind, placebo-controlled study of inter-
feron alfa-2a did not demonstrate any significant benefit from in-
terferon alfa-2a (Mariette 2000).
A single trial assessed the use of plasma exchange as additional
treatment to chlorambucil (Oksenhendler 1995). No additional
benefit was gained from the addition of plasma exchange in the
predefined outcomemeasures at four or 12months. This relatively
large study lacked blinding and allocation concealment, and the
results should therefore be interpreted with caution. Since the trial
showed no additional benefit from plasma exchange, any possible
bias did not lead to a significant result.
A number of case reports and small case series have described
use of rituximab for the treatment of paraproteinaemic neuropa-
thy (Barohn 2005; Benedetti 2005; Benedetti 2007; Benedetti
2008; Canavan 2002; Delmont 2010; Goldfarb 2005; Gono
2006; Gorson 2007; Kelly 2006; Kilidireas 2006; Latov 1999;
Levine 1999; Pestronk 2003; Renaud 2003; Renaud 2006; Weide
2000; Niermeijer 2009). The results were varied, with most re-
porting positive outcomes in themajority of participants but some
very usefully reporting no response in all their reported cases
(Barohn 2005; Rojas-García 2003), and some reporting deteriora-
tions (Broglio 2005; Gironi 2006; Noronha 2006). We included
the first rituximab RCT in the 2012 update (Dalakas 2009), and
we now include a further RCT (Léger 2013). Dalakas 2009 had a
high risk of bias in two assessed domains and unclear risks in three
others of the six assessed. As such, we assessed the evidence from
this trial as very low quality across the outcomes stipulated. The re-
sults should therefore be regarded with caution. With the removal
of a participant from the analysis who should perhaps not have
been randomised, the trial reported improvements in the INCAT
leg score and the 10-metre walk time, and in the whole group, the
IgM levels and anti-MAG titres. The study reported seven of 13
rituximab-treated participants compared to none of the 13 partic-
ipants in the placebo group experiencing improvement in “patient
clinical assessments and questionnaires”. In our analysis, although
there was a trend in favour of the treatment group in all analyses,
none of the clinical outcomes were statistically significantly dif-
ferent from placebo. However, rituximab did reduce IgM levels
and anti-MAG titres, as would be expected. The interpretation of
the results in the original paper by the trial authors concludes that
“The results warrant confirmation with a larger trial”. We have
now added the data from the larger and less biased Léger 2013
to the meta-analysis. Léger 2013 was reported as demonstrating
no change in its primary and secondary outcomes. However, the
outcome changes, where they are comparable, are all in a similar
direction and of similar magnitude to those of Dalakas 2009 (I
2 = 0% throughout). In meta-analysis, comparing rituximab to
placebo, significant improvements are seen in numbers of partici-
pants improved on the INCAT score (although the magnitude of
this does not reach clinical significance), the biological parameters
(IgM, anti-MAG titres), the physical subscores of the SF36 (but
not the mental), and perhaps importantly the patient clinical im-
pression of change scores, both for improvement alone and stabil-
isation and improvement. The numbers of participants are small
but the results demonstrate no heterogeneity. The results of Léger
2013 are more robust, at less risk of bias and more reliable, and
support an effect of rituximab in stabilising or improving anti-
MAG neuropathy.
Niermeijer 2007 trialed cyclophosphamide and corticosteroids
(CP) in combination, versus placebo. Ethical concerns led tomod-
ification of the protocol such that we could not use the data af-
ter the sixth month in the meta-analysis. We found no signifi-
cant improvements in the functional scales used (mRS and RMI),
as displayed here, from moderate-quality evidence. The trial re-
ports significant improvements in validated impairment measures
of strength and sensory dysfunction (not predefined outcomes in
this meta-analysis), which did not translate into functional bene-
fits.
This review has identified many problems with the trials of treat-
ment for this indication, including variations in trial design, par-
ticipant inclusion and exclusion criteria, analysis points, and out-
come measures. Only six of the eight trials were blinded. Some
trials employed a cross-over design, which must be allowed for in
analysis. In one study an alteration in the trial design for ethical
reasons meant that data beyond the six-month time point were
not usable in this analysis (Niermeijer 2007). Most studies did not
use validated clinical and disability scales that are likely to detect
changes (for example, the INCAT Sensory Sum Score (Merkies
2000)) and these should be considered in future studies. Further,
more sensitive scales measuring both disability and specific do-
mains of impairment that are affected in this predominantly sen-
sory neuropathy are being developed. Although Comi 2002 was
possibly too short to detect meaningful changes, it did include
validated, clinically useful, and reproducible endpoints such as the
sensory sum score, 10-metre walking time, nine-hole peg test, the
Rotterdam Scale (a handicap score), and the SF36 quality-of-life
scale. Dalakas 2009 also usedmore up-to-date outcomes, although
the trial was probably too small to detect significant change, and
bias makes the results unreliable. Further work is ongoing to de-
velop valid disability measures (see for example the PeriNomS
project). Objective endpoints such as presence of SNAPs were in-
frequently used, but in clinical practice these seldom change in
the short to medium term. No study has included a measure of
fatigue (Merkies 1999), which is prevalent in chronic inflamma-
tory demyelinating polyradiculoneuropathy but has not been in-
vestigated in anti-MAG neuropathy. Furthermore, effective treat-
ments, if identified, are likely to be expensive and possibly invasive,
and investigators should therefore consider measures of quality of
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life and cost effectiveness in all trials.
Only four trials confined recruitment to participants with anti-
MAG antibodies (Dalakas 2009; Léger 2013; Mariette 1997;
Mariette 2000). The anti-MAG neuropathies constitute the ma-
jority of the IgM paraproteinaemic demyelinating neuropathies
in terms of immunoreactivity. They are relatively homogeneous
in their clinical features and are distinct from some other rare
but identified subgroups (for example, those with IgM anti-GM1/
GD1b reactivity). Many IgM paraproteinaemic neuropathies have
no identified antigen target and yet are not clinically very different
from those with anti-MAG antibodies. This is often used as an
argument that anti-MAG antibodies are not relevant in the patho-
genesis. Although this may be the case, there is a considerable
body of evidence in favour of anti-MAG antibodies causing de-
myelination, as described in the Background. Lack of anti-MAG
antibodies may simply reflect low detection through inadequate
immunological identification, or alternative antigenic targets yet
to be described. Subgroup analysis by anti-MAG activity should
be reported in future trials.
Cochrane is increasingly concerned about the quality of data sup-
plied for systematic reviews from original trials where a number of
instances of fraudulent publishing have been uncovered. Any fu-
ture trials in the area should eradicate the need for suspicion about
the data published, by publishing, in full, the trial protocol on a
clinical trials website, making minimal change (but being trans-
parent with the change if required), publishing all the predefined
outcomes for all trials, and making the data available for scrutiny.
Non-randomised studies
As part of our systematic search of the literature for RCTs, we
identifiedmany case reports and small non-randomised case series.
These included all the therapies covered in the RCTs above, as well
as other therapies not subjected toRCTs. These are documented in
Table 3 but this should not be regarded as a systematic presentation
of the non-randomised literature.
Plasma exchange and apheresis
Dyck 1991 compared plasma exchange to sham exchange in a par-
allel-group RCT with 39 participants, 21 of whom had an IgM
paraprotein. We excluded this study, as there were no criteria spec-
ified for demyelination and the anti-MAG status was not clear.
Dyck 1991 found a significant improvement in the weakness com-
ponent of the Neuropathy Disability Score (now known as the
Neuropathy Impairment Score) in favour of plasma exchange in
the IgG and IgA, but not the IgM subgroups. Functional changes
were not reported. In eight case series of plasma exchange as
monotherapy, improvement was reported in 24 of 48 cases of IgM
paraprotein-associated neuropathy (Ellie 1996; Ernerudh 1986;
Ernerudh 1992; Frayne 1985; Gorson 1997; Gorson 2001; Haas
1988;Hafler 1986; Latov 1988;Nobile-Orazio 2000; Smith1987)
(see Table 3). When described, the improvement was sustained at
between eight and 36 months. Siciliano 1994 reported benefit in
one person with an IgM paraprotein treated with selective aphere-
sis, and Niemierko 1999 reported another. Improvement with
plasma exchange in combination with either pulsed intravenous
cyclophosphamide, chlorambucil, protein A immunoadsorption,
melphalan or adriamycin, with or without steroid, has been re-
ported in 25% to 100% of participants, all in small studies (one
to eight participants per treatment group) with follow-up periods
ranging from two to 34months (Bland 1985; Blume 1995; Dubas
1987; Gorson 2001; Kelly 1988; Latov 1980; Latov 1988; Meier
1984; Nobile-Orazio 2000; Oksenhendler 1995; Rudnicki 1998;
Sherman 1984; Smith 1987; Stefansson 1983; Tagawa 2001).
Corticosteroids
Less information is available regarding response to steroid ther-
apy. Four of five people treated with pulsed high-dose intravenous
dexamethasone improved, but the incidence of psychiatric side
effects (three of six, one with IgG MGUS) was unacceptably
high (Notermans 1997). Oral prednisolone alone objectively im-
proved only three of 30 people treated with monotherapy (Cook
1990; Dalakas 1981; Donofrio 1989; Ernerudh 1992; Gorson
1997; Gorson 2001; Hafler 1986; Latov 1988; Melmed 1983;
Nobile-Orazio 2000). Corticoteroids have been used in combi-
nation with azathioprine, cyclophosphamide, chlorambucil, and
plasma exchange in several small studies, with improvement or
stabilisation in 0% to 100% of participants at 14 to 54 months
follow-up (Dalakas 1981; Donofrio 1989; Ellie 1996; Ernerudh
1992; Kelly 1988; Latov 1988; Melmed 1983; Niermeijer 2007;
Nobile-Orazio 1988; Nobile-Orazio 2000; Notermans 1996;
Stefansson 1983).
Intravenous immunoglobulin
We have described the two RCTs of intravenous immunoglobulin
(IVIg) versus placebo above (Comi 2002: Dalakas 1996), which
provide low-quality evidence for very short-term improvement.
Six other uncontrolled studies reported transient improvement, in
22 of 50 participants, with IVIg (Cook 1990; Ellie 1996; Gorson
1997; Gorson 2001; Hoang-Xuan 1993; Léger 1994), whereas
another did not report improvement (Nobile-Orazio 2000).
Interferon alfa-2a
A well-performed randomised, double-blind, placebo-controlled
study of 24 people (Mariette 2000) confirmed the efficacy of in-
terferon alfa-2a as suggested by an earlier open study (see above).
One of eight people treated with interferon alfa-2a in a study by
Gorson et al improved (Gorson 2001). This participant remained
stable (mild bilateral foot drop and pinprick and vibration loss
in the feet, mRS 1) off all therapy for three years. Furthermore,
the IgM paraprotein and anti-MAG titre became unrecordable.
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A group of seven people treated with interferon alfa-2a, and as-
sessed with a novel measure of postural stability, improved (Pouget
2000).
Cytotoxic therapies
Chemotherapeutic (or cytotoxic) therapies have been used singly
or in combination with other drugs, but none (except Niermeijer
2007 using cyclophosphamide and corticosteroids, as above)
in a controlled trial. These agents include cyclophosphamide
(Blume1995;Gorson1997;Gorson 2001;Hafler 1986;Hamidou
2005; Kelly 1988; Niermeijer 2007; Nobile-Orazio 2000; Tagawa
2001), fludarabine (29 participants, 11 anti-MAG and nine of
these with clinical improvement) (Niermeijer 2006; Rudnicki
1998; Sherman 1994; Wilson 1999), fludarabine and rituximab
(Gruson 2011, see below), cladribine (one participant) (Ghosh
2002), azathioprine (Gorson 2001), mycophenolate (Gorson
2004), chlorambucil alone (Andres 2001; Gorson 2001; Latov
1988; Nobile-Orazio 2000), and melphalan and chlorambucil
(Ernerudh 1992). Responses to treatment were variable. More ex-
tensive chemotherapy has been used in non-MGUS associated
anti-MAG neuropathies, which are outside the scope of this re-
view (Andres 2001).
Rituximab
Rituximab has been used in multiple cases in non-randomised co-
horts and cases series (Barohn 2005; Benedetti 2005; Benedetti
2007; Benedetti 2008; Canavan 2002; Delmont 2010; Goldfarb
2005; Gono 2006; Gorson 2007; Kelly 2006; Kilidireas 2006;
Latov 1999; Levine 1999; Niermeijer 2009; Pestronk 2003;
Renaud 2003; Renaud 2006; Smith 2011; Weide 2000). About
50% to 60% of participants seem to respond in these uncon-
trolled studies, but two studies failed to show any benefit in five
participants (Barohn 2005; Rojas-García 2003), and three stud-
ies reported worsening (Broglio 2005; Gironi 2006; Noronha
2006). Three fully-published studies included42participantswith
anti-MAG neuropathy treated with rituximab and documented
improvements in strength, neurophysiological indices, and func-
tional score up to twoyears (Dalakas 2009; Pestronk 2003;Renaud
2003). However, neither Pestronk 2003 nor Renaud 2003 were
adequately controlled. Renaud 2003 had no controls and Pestronk
2003 had a semi-historical non-randomised control group with-
out blinding of the assessment of outcome measures. We describe
the first two RCTs of rituximab above (Dalakas 2009; Léger 2013)
A recent study describes the use of rituximab in combination with
fludarabine in five participants, four of whom improved clinically
and electrophysiologically, with serum IgM and anti-MAG titre
responses too. Improvement was sustained and, in this small series,
treatment was without significant toxicity (Gruson 2011).
Others
Some more novel therapies have been tried, including ciclosporin
in two participants (Hodgkinson 1990), and a single partici-
pant underwent autologous stem cell transplantation (ASCT)
(Rudnicki 1998). In this one person, the ASCTwas followed after
two years by improvements in symptoms, signs, and neurophys-
iological indices, although he had been treated with other agents
including fludarabine prior to the transplant. Neither ciclosporin
nor ASCT have been subjected to a RCT.
Economic considerations
The treatments discussed are all expensive. In 2005, the approxi-
mate cost of IVIg was about GBP 3600 for the standard 2.0 g/kg
dose in a 70 kg adult, and in 2012 about GBP 4500. Fludarabine
and rituximab cost approximately GBP 5000 per course, and an
autologous stem cell transplant costs approximately GBP 25,000
to 35,000. We cannot overstate the importance of subjecting such
agents to early and adequate clinical trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from trials of immunotherapies in anti-myelin-as-
sociated glycoprotein (anti-MAG) paraprotein-associated periph-
eral neuropathies is inadequate to identify whether any particu-
lar immunotherapy treatment is significantly beneficial. The eight
published randomised controlled trials (RCTs) of immunother-
apy in anti-MAG IgM paraproteinaemic neuropathy were all in-
dividually either too small, too short or too flawed for us to draw
confident conclusions about the efficacy of individual treatments
or comparisons between them.
In meta-analysis there is low-quality evidence (two small stud-
ies, one significantly biased including inconsistency, indirectness),
that rituximab is of benefit in stabilising or improving anti-MAG
neuropathy.
Implications for research
The statistically significant short-term benefit from IVIg may not
be clinically significant. The evidence is of low quality and needs
further confirmation. More large, carefully-constructed, collabo-
rative studies are required to identify whether anti-CD20 thera-
pies or other treatments are effective.
The IgM paraproteinaemic neuropathies are chronic and slowly
progressive. We chose to measure our outcomes at six and 12
months as these are more likely to reflect a time course over which
measurable progression or recoverymight occur. Endpoints of four
weeks or even three to four months may not be long enough to
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detect clinical stabilisation or improvement. Dalakas 2009, Léger
2013 and Niermeijer 2007 used sensible longer-term outcomes
and future studies should replicate this. We would encourage the
authors of future trials to collect consistent, comparable and clin-
ically-meaningful endpoint data. We predefined our primary out-
come measures as improvement in the Neuropathy Impairment
Scale and modified Rankin Scale (disability) at six months. The
inclusion of a disability measure in future trials would be appro-
priate, being relevant both to patients and to healthcare providers.
We have included Rasch-built disability scores in the secondary
outcome measures for future studies, as these show promise in re-
flecting change and more effectively representing a greater range
of disability. These remain in development and have not so far
appeared in any trial. Predictive scoring systems which allow the
clinician to estimate the trajectory and likely outcome of patients
at an early stage will allow people who warrant treatment to be
identified earlier in the disease; work needs to be undertaken to
study the natural history of the disease progression.
The Perinoms study is completed and a further study (Perinoms
2) is underway at the time of publication, which will define appro-
priate outcome measures for clinical and research outcome mea-
surement in this condition.
Studies of other novel agents such as cladribine or fludarabine may
be indicated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Comi 2002
Methods Randomised, double-blind, placebo-controlled cross-over trial
Participants 22 participants (11 with anti-MAG antibodies) with monoclonal gammopathy of unde-
termined significance, a stable or worsening demyelinating neuropathy and significant
limb disability. No other cause for neuropathy, treatment with IVIg, plasma exchange
or corticosteroids in the 6 weeks before randomisation or failure to respond to IVIg
previously
Interventions IVIg (2 g/kg) over 24 to 48 hours or placebo. Washout period and then cross-over
Outcomes Difference in overall disability grade 2 weeks from treatment
Secondary endpoints (2 and 4 weeks) were change in 10-metre walk time, average of
right and left hand times for 9-hole peg test, grip strength and vibration threshold, MRC
sum score, INCAT sensory sum score, sensory symptom score, Rotterdam Handicap
Scale, mRS and SF36
Nerve conduction studies at 4 weeks: distal CMAP amplitude, proximal CMAP ampli-
tude; motor conduction velocity
Funding Support from EUBIOMED project no. BMH4-CT96-0324. Novartis supplied San-
doglobulin and placebo infusions, and provided financial support
Conflicts of interest among main investi-
gators
Not provided
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk According to a sequence of random num-
bers provided by the trial statistician to the
manufacturers who prepared the randomi-
sation packs
Allocation concealment (selection bias) Low risk “The sequences were stratified by centre
with a block size of two according to a se-
quence of random numbers provided by
the trial statistician to the manufacturers
who prepared the randomisation packs.
The block size was not revealed to the trial-
ists. Each centre was provided with coded
packs, prepared by Novartis, containing ei-
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Comi 2002 (Continued)
ther Sandoglobulin or placebo.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The placebo infusions contained albumin
6 mg % and were identical in appearance
to the IVIg infusions”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The placebo infusions contained albumin
6mg% and were identical in appearance to
the IVIg infusions”; “The assessing neurol-
ogist, who did not have access to laboratory
data or to possible side effects, performed
all trial assessments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “According the intention-to-treat principle
with themethods described by Senn” (Senn
1993). “All participants completed study.”
Selective reporting (reporting bias) Low risk None
Other bias Low risk None
Dalakas 1996
Methods Randomised, placebo-controlled cross-over trial
Participants 11 participants were randomised of whom 9 had IgM anti-SGPG activity. All had de-
myelinating neuropathy. All had subjective worsening in the 9 to 12 months prior to
study and 9 were unresponsive to prior therapies
Interventions IVIg (2 g/kg) or placebo over 2 days monthly for 3 months. Washout period and then
crossed over to alternative arm
Outcomes MRCmuscle strength, neuromuscular symptoms score and sensory sum score at baseline,
end of washout and end of each treatment period. Anti-MAG titres at various times
during the protocol. No primary outcome measure was predefined
Funding Bayer Pharmaceuticals provided the IVIg
Conflicts of interest among main investi-
gators
Not declared
Notes No criteria for demyelination were stated. No explicit exclusion of other causes of neu-
ropathy
Risk of bias
Bias Authors’ judgement Support for judgement
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Dalakas 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk Possibly generated in National Institutes
of Health pharmacy, but unclear by what
methodology
“Randomized” but no method given. A
block-randomisation procedure was used
in 1993 dermatomyositis trial which is ref-
erenced
Participants randomised to placebo were
much older than in the IVIg arm, although
this did not reach significance with the
nine anti-MAGparticipants included. Sen-
sory scores were significantly higher in the
placebo group than the IVIg-treated group
Allocation concealment (selection bias) Unclear risk Generated in National Institutes of Health
pharmacy but placebo was dextrose in half-
normal saline. The code was broken when
all participants completed the study. Allo-
cation concealment is referred to as having
been performed as per the 1993 dermato-
myositis trial referenced in the paper
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The whole intravenous set was covered by
an opaque plastic bag so that any possi-
ble fluid turbidity or frothing would not
be evident to the investigators or patients.
None of the laboratory values were entered
into the computer or the patients’ charts.”
- derived from referenced 1993 study. “The
physicians, nurses, physical therapists, pho-
tographer, and statistician were unaware of
which treatment was administered”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The whole intravenous set was covered by
an opaque plastic bag so that any possible
fluid turbidity or frothing would not be ev-
ident to the investigators or patients. None
of the laboratory values were entered into
the computer or the patients’ charts.” - de-
rived from referenced 1993 study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how incomplete data analysed -
participant 7 did not participate in arm
2 but data presented - thus no treatment
given
Selective reporting (reporting bias) Unclear risk None identified but predates
ClinicalTrials.gov
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Dalakas 1996 (Continued)
Other bias Low risk None identified
Dalakas 2009
Methods Randomised, double-blind parallel-group study
Participants 26 participants, selected if they had clinical and electrophysiological evidence of a de-
myelinating neuropathy, a benign IgM monoclonal spike, and anti-MAG or SGPG an-
tibodies. Participants should not have received any immunosuppressive therapy for at
least 6 months before enrolment. At entry, all participants should have impaired func-
tion as evidenced by affected balance, co-ordination, frequent falls, or muscle weakness,
reflected in an INCAT disability (leg) score > 1
Interventions Rituximab 375 mg/m2 i.v. 4 times, given weekly
Outcomes The primary outcome was a change of 1 point in INCAT disability scale score in the
lower extremities at month 8
Secondary measures included assessment of sensory function using the SNS scale and
muscle strength measurements using the MRC scale.
Electrophysiological outcomes: median, ulnar, tibial, and peroneal motor and sensory
nerve conduction velocities were determined before therapy and at the end of the 12-
month follow-up period
Funding “The study was conducted at the National Institutes of Health under a Cooperative
Research and Development Agreement between National Institute of Neurological Dis-
orders and Stroke and Genetech [sic]”
Conflicts of interest among main investi-
gators
“Nothing to report”
Notes Statistical manipulations cause concern. One participant was removed from the study
after randomisation because a severe adverse event occurred on 1st infusion of the drug,
and was not analysed. One participant was mis-scored with INCAT 1 but on analysis
was found to be INCAT 0 and hence excluded from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper states “Randomized” only
Allocation concealment (selection bias) Unclear risk Not clear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both drug and placebo were supplied by
theNational Institutes of Health pharmacy
and sent to the floor covered so that all in-
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Dalakas 2009 (Continued)
vestigators, assessors, evaluators, and nurses
remained blinded to the study code
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Both drug and placebo were supplied by
theNational Institutes of Health pharmacy
and sent to the floor covered so that all in-
vestigators, assessors, evaluators, and nurses
remained blinded to the study code
Incomplete outcome data (attrition bias)
All outcomes
High risk One participant removed after randomisa-
tion following adverse events replaced by
another and not included in the analysis.
One participant admitted to study who
could not have improved and thus removed
from the analysis. The analysis was per-
formed both with and without this partic-
ipant
Selective reporting (reporting bias) High risk See section above
Other bias High risk Data check of publication inconsistencies
verbally clarified. Study authors unable to
provide participant-level data for outcomes
checking and reformatting
Trial not registered on ClinicalTrials.gov
Non-balanced groups with respect to sex at
admission, not representative of disease
Drug company provided drug
Léger 2013
Methods A randomised, double-blind, placebo-controlled study
Participants 54 participants between 18 and 82 years of age with demyelinating sensory ataxic neu-
ropathy associated with anti-MAG IgM gammopathy, a demyelinating neuropathy ac-
cording to EFNS/PNS criteria, and either monoclonal gammopathy of unknown sig-
nificance or a low-grade non-Hodgkin B-cell lymphoma not necessitating treatment by
itself. The presence of serum anti-MAG antibodies at significant titres was assessed by
1 reference laboratory. For inclusion in the trial, the patients had an INCAT score 4 or
more, and VAS pain score > 4 or an ataxia score of 2 or more
Interventions Either weekly infusions of 375 mg/m2 rituximab for 4 weeks (n = 26) or identical
infusions of placebo (n = 28)
Outcomes Primary outcome: 20% improvement of the INCAT score at 12 months
Secondary outcome measures: sensory part of the Neurological Disability Score, MRC
scale in distal muscles in both upper and lower limbs, ataxia score, 10-meter walking
time, self-evaluation scale, electrophysiological and immunological data
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Léger 2013 (Continued)
Funding Roche France provided the rituximab and placebo. Study supported by academic grant
Conflicts of interest among main investi-
gators
Full disclosures made by authors (see www.neurology.org). No author reported conflicts
related to Roche or Genentech
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a stratified (by centre) and blocked
(with variable block length) randomisation
list (created by a statistician) to ensure that
the 2 parallel groups were comparable at
baseline, participants were randomised by
fax to 1 of 2 groups (1:1 ratio)
Allocation concealment (selection bias) Low risk “The first group received 4weekly infusions
of 375 mg/m2 rituximab (as in regimens
used in previous trials for IgM anti-MAG
demyelinating neuropathy) and the second
group received placebo”
It is not clear that allocation concealment
to group was maintained. However, “Ran-
domization was centralized and carried out
independently of the clinicians.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Drug and placebo were supplied by Roche
France.” “All investigators, assessors, eval-
uators, and nurses remained blinded to the
randomization codes.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All investigators, assessors, evaluators, and
nurses remained blinded to the randomiza-
tion codes.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome measures from the methods
reported
Selective reporting (reporting bias) High risk None identified. The trial protocol on
ClinicalTrials.gov does not specify all the
outcomes listed in themethods, giving only
functional scales (MRC), quality of life,
serum lymphocyte, anti-MAG titres and
electrophysiological parameters
Other bias Low risk None
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Mariette 1997
Methods Randomised, open, parallel-group trial
Participants 20 participants with stable or progressive anti-MAG neuropathy with CNDS > 10, with
no other cause for neuropathy and no treatment in preceding 3 months
Interventions IVIg (2 g/kg) over 4 days, then IVIg 1 g/kg over 2 days every 3 weeks for 6 months, then
every 6 weeks for 6 months if CNDS improvement > 20%
Or interferon alfa-2a 3 MU/m2 3 times a week for 6 months and then twice a week if
CNDS improvement > 20%. If no improvements at 6 months then participants crossed
over
Outcomes Change in CNDS at 6 months. Secondary endpoints were proportion of participants
with 20% improvement in CNDS, improvement in CNDS at 12 months, change in
electrophysiological data, change in level of monoclonal component, change in anti-
MAG titre, subjective score
Funding “Drug and placebo were supplied by Roche France.”
Conflicts of interest among main investi-
gators
None declared
Notes 11 participants treated with plasma exchange (3) or chlorambucil (8) without benefit
prior to trial
Some participants changed over to the alternate (open) arm if they failed to respond at
6 months or declined sooner (one participant in the IVIg arms switched at 4 months).
Data for this participant or those who dropped out were included on a ’last observation
carried forward’ intention-to-treat basis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stratified randomisation according to previ-
ous treatment through a blinded telephone as-
signment procedure
Allocation concealment (selection bias) High risk No - open
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No - open
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No - open
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat analysis using ’last observa-
tion carried forward’. Small numbers of par-
ticipants, with a high level of dropout, and
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Mariette 1997 (Continued)
early cross-over
Selective reporting (reporting bias) Low risk No selective reporting identified
Other bias High risk 4/10 participants dropped out of IVIg group,
and study interrupted after first interim anal-
ysis
Mariette 2000
Methods Prospective, randomised, double-blind, placebo-controlled trial
Participants 24 participants with stable or progressive anti-MAG neuropathy with CNDS > 10, no
other cause for neuropathy and no treatment in preceding 3 months
Interventions Interferon alfa-2a 4.5 MU 3 times a week for 6 months, or visually identical placebo
Outcomes Change in CNDS at 6 months. Secondary endpoints were proportion of participants
with a 20% improvement in CNDS and a participant subjective score
Funding Academic grant from public body - unclear if drug supply also from company as in
Mariette 1997
Conflicts of interest among main investi-
gators
None declared
Notes 11 (5 in interferon, 6 in placebo group) had been previously treated with chlorambucil
with no effect and 10 also with plasma exchange
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stratified randomisation according to the
existence of a previous treatment, through
a blinded telephone assignment procedure
“Randomly Allocated”
Allocation concealment (selection bias) Low risk Blinded telephone assignment procedure
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The reconstituted vials of interferon alfa-2a
or placebo were delivered by the pharmacy
of each centre and appeared identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
35Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mariette 2000 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Yes - explained in the report. Intention-to-
treat analysis using ’last observation carried
forward’
Selective reporting (reporting bias) Low risk Yes
Other bias Low risk Yes - except trial stopped early because no
placebo left
Niermeijer 2007
Methods Randomised, double-blind, placebo-controlled, partial cross-over study of 24 months
duration. Participants who declined at 6 months were crossed-over to the other group.
Analysis at 6 months then again with 2nd treatment group
Participants 35 participants, 17/35 with anti-MAG antibodies. Men or women. Inclusion criteria
were a diagnosis of symmetric motor and sensory polyneuropathy confirmed by elec-
trophysiologic examination; presence of a monoclonal IgM gammopathy, progression
of symptoms defined as a ?1 point deterioration on the mRS or RMI, or a ?5% dete-
rioration of the MRC sum score or sensory sum score in a time interval of 6 months;
no other causes for polyneuropathy; age over 25 years and completed family for reasons
of fertility; no underlying haematologic malignancies as excluded by a haematologist;
no contraindications for the use of corticosteroids or cyclophosphamide; no other im-
munotherapy for polyneuropathy in the previous 5 years
Interventions Cyclophosphamide 500 mg orally once daily for 4 days with prednisone 60 mg orally
once daily for 5 days. Given every 28 days for 6 to 12 months, depending upon cross-
over
Outcomes Primary outcome - revised RMI: Change from baseline on the RMI was compared
between the treatment group and placebo group, as well as percentage responders from
6 to 24 months after start of treatment. Response was defined as 1 point improvement
on the RMI
Secondary outcome measures: Changes from baseline at 6, 12, 18, and 24 months using
mRS,MRC sum score (0 to 140 points), manual muscle testing (MMT) using theMRC
scale in 28 muscles of both arms and legs. Sensory sum score (0 to 56 points). Ataxia was
scored with a standardised tapping test of the dominant hand and foot measuring the
number of taps using a device with 2 buttons attached to an automatic counter. Quality
of life - Dutch SF 36 questionnaire. M-protein levels
Electrophysiologic studies (before and 6 months after start of treatment): motor con-
duction with stimulation of the median, ulnar, peroneal nerve and tibial nerve. Sensory
conduction of musculocutaneous, median, ulnar, radial, and sural nerves on distal stim-
ulation was measured
Funding Not declared
Conflicts of interest among main investi-
gators
“The authors report no conflicts of interest.”
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Niermeijer 2007 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated to treatment or
placebo using a computer-generated list
with permuted blocks of randomly varying
size stratified by anti-MAG activity
Allocation concealment (selection bias) Low risk Physicians and participants were unaware
of treatment allocation throughout the
study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were unaware of treatment al-
location throughout the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physicians were unaware of treatment allo-
cation throughout the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat
8/35 participants dropped out over 2 years.
Only 1 participant dropped out and lost
to follow-up before 6 months. Another
stopped drug but continued follow-up.
Only 1 analysed in final by intention-to-
treat
Selective reporting (reporting bias) Low risk None
Other bias Low risk None identified
Oksenhendler 1995
Methods Prospective randomised open, parallel-group trial
Participants 44 participants with IgM associated peripheral neuropathy of whom 33 had serum IgM
anti-myelin activity. Not necessarily demyelinating
Interventions Chlorambucil alone (0.1 mg/kg/day orally) for 12 months or in association with 15 1½-
volume plasma exchanges over 4 months
Outcomes Primary outcome measure was the NDS after 12 months. Secondary endpoints were
changes in the sensory or motor subcomponents of the NDS, participant subjective self-
assessment and neurophysiological studies
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Oksenhendler 1995 (Continued)
Funding Not known
Conflicts of interest among main investi-
gators
None declared
Notes 45 participants were initially enrolled. 1 randomised to the chlorambucil group had
severe chronic hepatopathy and the data were excluded
10 participants had suspension or dose reduction of chlorambucil because of haemato-
logical toxicity. 8 participants (4 in each group) failed to complete the trial to 12 months,
but were included in intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were assigned by randomisa-
tion”
Allocation concealment (selection bias) High risk No - open
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No - open to participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not clear for assessors - probably no
Incomplete outcome data (attrition bias)
All outcomes
High risk All outcomes are reported but incomplete
follow-up and dropouts are not reported
Mention of intention-to-treat analysis is
passing only. Unclear whether applied to all
outcomes
1 participant from chlorambucil group had
a hepatopathy and their data were not in-
cluded in the analysis
Selective reporting (reporting bias) Low risk None
Other bias High risk 3 participants on chlorambucil stopped
treatment by months 2, 7, and 9, and sub-
sequently received plasma exchange. They
were, however, included in the chlorambu-
cil group analysis on an intention-to-treat
basis but the effect of plasma exchange is
unclear
anti-MAG: anti-myelin-associated glycoprotein
38Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CMAP: compound muscle action potential
CNDS: Clinical Neuropathy Disability Score
IgM: immunoglobulin M
INCAT: Inflammatory Neuropathy Cause and Treatment
IVIg: intravenous immunoglobulin
MRC: Medical Research Council
mRS: modified Rankin Scale
NDS: Neuropathy Disability Score
RMI: Rivermead Mobility Index
SF36: Short Form 36 Health Survey
SGPG: sulphated glucuronyl paragloboside
SNSS: sensory neuropathic sum scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barohn 2005 Uncontrolled open study
Benedetti 2005 Uncontrolled open study
Benedetti 2007 Uncontrolled open study
Benedetti 2008 Uncontrolled case series
Canavan 2002 Uncontrolled open study
Dyck 1991 Participants with IgM paraprotein had no documentation of anti-MAG status. No criteria for the diagnosis of
demyelination
Goldfarb 2005 Single case
Gorson 2004 8 participants in open uncontrolled study of mycophenolate
Gorson 2007 Uncontrolled open study including single participant with anti-MAG antibody
Hamidou 2005 Uncontrolled study of 9 participants
Kilidireas 2006 Uncontrolled open study
Latov 1999 Open study
Niermeijer 2006 Open uncontrolled follow-up
Niermeijer 2009 Case series
Pestronk 2003 Non-randomised control group and unblinded assessments
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(Continued)
Renaud 2003 Open study
Renaud 2006 Open uncontrolled follow-up study
Sghirlanzoni 2000 Open uncontrolled study - 8 IgM in 60 participants
Smith 2011 Non-randomised phase II clinical trial - case series
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D A T A A N D A N A L Y S E S
Comparison 1. IVIg versus interferon alfa-2a
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in Clinical Neuropathy
Disability Score (CNDS) at six
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Subjective score at six months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Number of participants
improved by at least 20% on
NIS at 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Interferon alfa-2a versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in the CNDS at 6
months (maximum 93)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Number improved in CNDS by
20% at 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. Rituximab versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants
improved on INCAT score (see
text) at 8-12 months
2 73 Risk Ratio (M-H, Fixed, 95% CI) 3.51 [1.30, 9.45]
2 Mean improvement in INCAT
score (see text) at 8 - 12 months
2 73 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.85, -0.05]
3 Rituximab vs placebo. Mean
improvement in INCAT score
at 8 - 9 months (post hoc data)
2 70 Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.73, 0.07]
4 Mean improvement in NIS at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Improvement in 10-metre walk
time at 8 - 12 months
2 68 Mean Difference (IV, Fixed, 95% CI) -0.35 [-1.89, 1.19]
6 Number improved in 10-metre
walk at 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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7 Change in IgM level 8 months
after treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Change in IgM anti-MAG titre
at 8 - 12 months
2 71 Mean Difference (IV, Fixed, 95% CI) -17.79 [-33.33, -2.
25]
9 Participant subjective impression
of change stable or improved at
8 - 12 months
2 70 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.27, 2.71]
10 Participant subjective
impression of change improved
at 8 - 12 months
2 70 Risk Ratio (M-H, Fixed, 95% CI) 9.67 [1.84, 50.85]
11 Mean change in SF36 physical
subscores at 12 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12 Mean change in SF36 mental
health subscores at 12 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Any adverse event 2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.84, 1.66]
14 Severe adverse event 2 80 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [0.34, 28.54]
Comparison 4. Cyclophosphamide and steroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in modified
Rankin Scale at 6 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Number of participants
improved on modified Rankin
Scale at 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Improvement in Rivermead
Mobility Index (subjective
participant score) at 6 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. ’Summary of findings’ table: Intravenous immunoglobulin (IVIg) versus placebo
IVIg versus placebo for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
Patient or population: people with IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
Settings: hospital and outpatient treatment centres
Intervention: IVIg versus placebo
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
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Table 1. ’Summary of findings’ table: Intravenous immunoglobulin (IVIg) versus placebo (Continued)
Risk with
placebo
Risk with IVIg
Number of par-
ticipants im-
proved in dis-
ability score at 6
months - not re-
ported
See comment See comment Not estimable - See comment Short-term out-
comes only,
not reported at 6
months
Mean improve-
ment in disabil-
ity score at 6
months - not re-
ported
See comment See comment Not estimable - See comment Short-term out-
comes only,
not reported at 6
months
Improve-
ment in 10-me-
tre walk time at
6 months - not
reported
See comment See comment Not estimable - See comment Short-term out-
comes only,
not reported at 6
months
Participant sub-
jec-
tive impression
of change at 6
months - num-
ber of partici-
pants reporting
improvement -
not reported
See comment See comment Not estimable - See comment Short-term out-
comes only,
not reported at 6
months
Change
in serum IgM
parapro-
tein concentra-
tion 8 months
after treatment -
not reported
See comment See comment Not estimable - See comment Short-term out-
comes only,
not reported at 6
months
Any adverse
event
Data for the anti-MAG subgroup
were not available. In one study, one
participant had an aseptic meningi-
tis and a rash after IVIg treatment,
with 2 moderate adverse events in
the placebo group. In the other trial,
there were no serious adverse events
with IVIg, but mild and transient
Not estimable - See comment No further anal-
ysis was possible.
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Table 1. ’Summary of findings’ table: Intravenous immunoglobulin (IVIg) versus placebo (Continued)
effects were “more common in the
IVIg than the placebo group”
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Incomplete reporting of adverse events in one study.
Table 2. ’Summary of findings’ table: Cyclophosphamide and prednisone versus placebo
Cyclophosphamide and corticosteroids compared to placebo for IgM anti-myelin-associated glycoprotein paraprotein-asso-
ciated peripheral neuropathies
Patient or population: people with IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
Settings: hospital and outpatient treatment centres
Intervention: cyclophosphamide and corticosteroids
Comparison: placebo
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with cyclo-
phospha-
mide and corti-
costeroids
Number of par-
ticipants im-
proved in dis-
ability score at 6
months
Modifed Rankin
Scale
Scale from:
0 to 6 (normal to
death)
Follow-up:mean
Study population RR 3.56
(0.41 to 30.99)
35
(1 study)
⊕⊕⊕©
moderate1
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Table 2. ’Summary of findings’ table: Cyclophosphamide and prednisone versus placebo (Continued)
6 months
53 per 1000 189 per 1000
(22 to 1000)
Mean improve-
ment in disabil-
ity score at 6
months
Modifed Rankin
Scale
Scale from:
0 to 6 (normal to
death)
Follow-up: 6
months2
The mean
improvement in
disability score at
6 months in the
control groups
was
0.11 units
The mean
improvement in
disability score at
6 months in the
intervention
groups was
0.31 lower
(0.61 lower to 0.
01 lower)
34
(1 study)
⊕⊕⊕©
moderate1
Improve-
ment in 10-me-
tre walk time at
6 months - not
reported
See comment See comment Not estimable - See comment Not reported
Participant sub-
jec-
tive impression
of change at 6
months - num-
ber of partici-
pants reporting
improvement -
not reported
See comment See comment Not estimable - See comment Not reported
Change
in serum IgM
parapro-
tein concentra-
tion after treat-
ment - not re-
ported
See comment See comment Not estimable - See comment Not reported
Any adverse
event
- not measured
See comment See comment Not estimable - See comment Ad-
verse events not
specifically col-
lected but text
notes in the pa-
per (see text of
review)
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Table 2. ’Summary of findings’ table: Cyclophosphamide and prednisone versus placebo (Continued)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; IgM: immunoglobulin M; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Dowgraded once for imprecision (single small study).
2Phase 1 of cross-over trial only.
Table 3. Details of non-randomised studies
Study ID Study design Parti-
ciant number
(total)
Partic-
ipant number
(IgM)
Partic-
ipant number
(MAG)
Intervention Number im-
proved (IgM)
Num-
ber improved
(MAG)
Latov 1980 Case report 1 1 1 (anti-myelin
Abs)
Prednisolone
+ chlorambu-
cil + plasma
exchange
1/1 -
Dalakas 1981 Uncon-
trolled case se-
ries (response
to Rx recorded
inLatov 1988)
11 4 ? a. Pred-
nisolone b.
Prednisolone
+ chlorambu-
cil
a. 0/1 b. 1/1 -
Melmed 1983 Uncon-
trolled case se-
ries (response
to Rx recorded
inLatov 1988)
3 3 3 a. Cor-
ticosteroids b.
Steroids
+ plasma ex-
change + chlo-
rambucil
- a. 3/3 b. 0/3
Stefansson
1983
Case report 1 1 1 Plasmaphere-
sis + immuno-
suppressant
- 0/1
Meier 1984 Case report 1 1 1 Plasmaphere-
sis + pred-
nisolone +
chlorambucil
- 1/1
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Table 3. Details of non-randomised studies (Continued)
Sherman
1984
Retrospective
case series
10 6 ? Plasmaphere-
sis + chloram-
bucil
2/5 -
Bland 1985 Case report 1 1 1 Plasmaphere-
sis + chloram-
bucil
- 1/1
Frayne 1985 2 cases 2 2 - Plasma
exchange
2/2 -
Ernerudh
1986
Retro-
spective non-
randomised
3 3 3 (anti-myelin
Abs)
Plasma
exchange
2/3
(temporary)
-
Hafler 1986 Uncon-
trolled case se-
ries (response
to Rx recorded
inLatov 1988)
9 9 7 a.Cor-
ticosteroids b.
Plasma ex-
change c. Cy-
clophospha-
mide
- a. 0/5 b. 1/5 c.
1/1
Smith 1987 Prospec-
tive non-ran-
domised case
series
13 8 (2
lymphoma)
4 (1
lymphoma)
a. Chloram-
bucil + plasma
exchange
b. Plasma ex-
change
a. 3/4 b. 1/2 a. 1/2 b. 1/1
Haas 1988 Case report 1 1 1 Plasma
exchange
1/1 1/1
Kelly 1988 Uncontrolled
case series
10 10 5 Prednisolone
+ cyclophos-
phamide (aza-
thioprine
or chlorambu-
cil) + plasma
exchange
4/4 (all 5 not
treated)
2/3 (All 5 not
treated)
Latov 1988 Uncontrolled
case series
11 11 11 a. Plasma-
pheresis b.
Prednisolone
c. Chloram-
bucil d. Pred-
nisolone
+ plasma ex-
change
e. Plasma ex-
- a. 3/3 b. 0/1 c.
3/4 d. 0/1 e. 0/
1
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Table 3. Details of non-randomised studies (Continued)
change + chlo-
rambucil
Donofrio
1989
Case report 1 1 0 a. Cor-
ticosteroids b.
Plasma ex-
change + cor-
ticosteroids
a. 0/1 b. 1/1 -
Cook 1990 Case reports 2 2 1 a. IVIg b.
prednisolone
a. 2/2 a. 1/1 b. 0/1
Hodgkinson
1990
Uncontrolled
case series
8 2 ? Ciclosporin 2/2 -
Ernerudh
1992
Prospec-
tive non-ran-
domised
5 5 5 (anti-myelin
Abs)
a. Plasma ex-
change b.
Prednisolone
c. Melphalan
d. Chloram-
bucil e. Chlo-
rambu-
cil and plasma
exchange
f. Chlorambu-
cil +
prednisolone
a. 1/1 b. 1/2 c.
0/1 d. 0/1 e. 1/
1 f. 1/2
-
Hoang-Xuan
1993
Open
prospective
4 4 3 (2 in Léger
1994)
IVIg - 0/1
Léger 1994 Open
prospective
7 7 5 IVIg - 2/5
Sherman
1994
Abstract 10 10 8 Fludarabine - 7/8
Siciliano 1994 Case report 3 1 ? Selective
apheresis
1/1 -
Blume 1995 Uncontrolled
case series
4 3 4 Plasma
exchange + cy-
clophospha-
mide
3/3 4/4
Ellie 1996 Retrospective
case series
33 33 33 a. Plasma ex-
change b. IVIg
a. 2/6 b. 13/17 -
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Table 3. Details of non-randomised studies (Continued)
Notermans
1996
Open
prospective
16 11 5 Cyclophos-
phamide +
prednisolone
- Unclear
Gorson 1997 Retrospective
case series
15 12 8 a. Plasma ex-
change b.
Prednisolone
c. IVIg d. Cy-
clophospha-
mide + plasma
exchange
a. 10/12? b. 1/
2 c. 2/6 d. 2/2
Unclear
Rudnicki
1998
Case report 1 1 1 a. Fludarabine
+ plasma ex-
change
b. Bone mar-
row transplant
a. 0/1 b. 0/1
Latov 1999 Case reports 2 2 2 Rituximab - 1/2
Levine 1999 Probably
included in
Pestronk 2003
- unclear
- - - Rituximab - -
Wilson 1999 Open
prospective
4 4 4 Fludarabine - 4/4
Nobile-
Orazio 2000
Retrospective
case series
25 25 25 a. Plasma ex-
change
b. Plasma ex-
change + chlo-
ram-
bucil c. Pred-
nisolone d.
IVIg e. Cyclo-
phosphamide
a. 2/5 b. 2/2 c.
0/6 d. 0/2 e. 1/
5
Gorson 2001 Retrospective
case series (NB
some cases in
Gorson 1997)
24 22 24 a. Plasma ex-
change b. IVIg
c.
Prednisolone
d. Cyclophos-
phamide
e. Plasma ex-
change + cy-
clophos-
phamide f. In-
- a. 8/20 b. 3/19
c. 0/8 d. 3/6 e.
2/8 f. 1/8 g. 0/
2 h. 0/2
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Table 3. Details of non-randomised studies (Continued)
terferon alfa-
2a g. Chlo-
rambucil h.
Azathioprine
Tagawa 2001 Case report 1 1 1 Plasmaphere-
sis + cyclo-
phosphamide
- 1/1
Canavan
2002
Retrospective
case reports
(abstract)
3 3 2 Rituximab - 1/2
Ghosh 2002 Case report 1 1 1 Cladribine - 1/1
Pestronk
2003
Prospective
open study
21 21 7 Rituximab - Unclear - im-
provement
Renaud 2003 Prospective
open phase II
study
9 9 9 Rituximab - 6/9
Barohn 2005 Uncontrolled
case series
5 5 3 Rituximab 0/5 0/3
Benedetti
2005
Uncontrolled
?prospective
(abstract)
13 13 13 Rituximab - 8/13
Broglio 2005 Case report 1 1 1 Rituximab - Worse
Hamidou
2005
Uncontrolled
case series
9 9 - Cyclophos-
phamide
7/9 improved,
2 stable
-
Kilidireas
2006
Uncontrolled
case series
4 4 2 Rituximab 3/4 improved
Niermeijer
2006
Open
prospective
16 16 6 Fludarabine 3/
10 improved,
all others sta-
bilised
2/6 improved
all others sta-
bilised
Renaud 2006 Prospec-
tive follow-up
study to 2003
8 8 8 High-dose rit-
uximab
- 4/7 improved
(1 death)
Gironi 2006 Case report 1 1 1 Rituximab - Worse
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Table 3. Details of non-randomised studies (Continued)
Noronha
2006
Case report 1 1 Rituximab - Worse
Niermeijer
2009
Case series 17 17 6 Rituximab Improvement
in:
ODSS 2/17,
MRC sum
score 11/17,
Sensory sum
score 10/17
3/6
Delmont
2010
Case report 1 1 0 Rit-
uximab (after
IVIg, corticos-
teroids, chlo-
rambucil)
1 N/A
Gruson 2011 Case series 5 5 (2 MGUS, 3
WM)
5 Ritux-
imab and flu-
darabine
4/5 improved
clinically, elec-
trophysio-
logically, IgM
level and anti-
MAG titre
All MAG
Smith 2011 Phase II non-
randomised
case series
21 21 N/K Rituximab NIS sig-
nificant (>10
pts) improve-
ment at
6 months 13/
21, and 24
months 8/21
N/A
Abs: antibodies; anti-MAG; anti-myelin-associated glycoprotein; IgM: immunoglobulin M; IVIg; intravenous immunoglobulin; pts:
participants; Rx: treatment; WM: Waldenstrom’s macroglobulinemia
WH A T ’ S N E W
Last assessed as up-to-date: 1 February 2016.
Date Event Description
1 February 2016 New citation required and conclusions have changed New trials have been incorporated,which change the con-
clusions of the review
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(Continued)
1 February 2016 New search has been performed We added a new secondary outcomemeasure of a R-ODS
score or similar to bring the review into line with current
thinking on outcome measures in paraproteinaemic neu-
ropathies
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 1, 2003
Date Event Description
22 November 2011 New citation required and conclusions have changed New studies that included new interventions were in-
cluded and these changed the conclusions of the re-
view
25 October 2011 New search has been performed Searches were updated to June 2011.
New ’Risk of bias’ methodology was included.
In this update, data were extracted independently and
cross-checked; in the previously published version,
data were extracted by one author and checked by the
other
29 May 2008 Amended Converted to new review format.
2 January 2006 New citation required and conclusions have changed We updated the Cochrane Neuromuscular Disease
Group Register in March 2005 and searched MED-
LINE (January 1966 to March 2005) and EMBASE
(January 1980 to March 2005). We have added com-
ments about two non-randomised trials of rituximab
in the treatment of IgM anti-myelin associated glyco-
protein (MAG) paraproteinaemic demyelinating pe-
ripheral neuropathy. There are three other non-ran-
domised rituximab studies published in abstract form.
We have amended the ’Discussion’ and ’Conclusion’
of the review accordingly
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C O N T R I B U T I O N S O F A U T H O R S
Michael Lunn prepared the first draft of the review, prepared databases for the extraction of data from the reviews, extracted data and
prepared edits in subsequent drafts.
Eduardo Nobile-Orazio extracted data independently, edited each draft and agreed the final text.
D E C L A R A T I O N S O F I N T E R E S T
MPTL has published a pilot study of the use of fludarabine in IgM-associated paraproteinaemic neuropathy (Wilson 1999) and was a
blinded investigator in Comi 2002. He has received honoraria for consultation from Baxter Pharmaceuticals, CSL Behring, UCB and
LFB and a travel support grant from CSL Behring and Grifols, all manufacturers of IVIg. He was a blinded Site Investigator on the
FORCIDP study (fingolimod in CIDP (Novartis) who in August 2015 purchased ofatumumab (not included in this review). He is
Joint Co-ordinating Editor of Cochrane Neuromuscular. He did not have a role in editorial assessment or the decision to publish this
updated review.
EN-O has received honoraria from CSL Behring (Italy and USA), UCB (UK), and Kedrion (Italy) for Scientific Advisory Board
participation and from Novartis (Switzerland) for being part of a Steering Committee for a trial with fingolimod on CIDP. He received
compensation from Baxalta, Italy for preparing a teaching course on Multifocal Motor Neuropathy. He received compensation for
lectures from Kedrion, Italy, CSL Behring, Italy and Baxter, USA. He received support for Meeting attendance from CSL Behring, Italy
and Kedrion Italy. He has published a study of long-term prognosis of IgM neuropathies and their immunotherapy (Nobile-Orazio
2000) and was a member of the BIOMED INCATGroup which conducted the Comi 2002 study. He was the principal investigator in
a RCT sponsored by Kedrion comparing the efficacy of intravenous corticosteroids with IVIg in CIDP. He is the Principal Investigator
of a trial on IVIg in CIDP sponsored by LFB, France. He states that no part of the above-mentioned financial support had any influence
on his work in preparing this review.
Both review authors were investigators in Comi 2002. The Cochrane Neuromuscular Managing Editor carried out an independent
risk of bias assessment and data extraction of outcome data for this study, and checked these against the data entered in the review.
This review was first published in 2003. One new trial, of rituximab, has been added at this update. Both review authors have declared
financial remuneration for consultancy work relating to IVIg. The most recent trial of IVIg was published in 2002, the conclusion
of the review being that the short-term effects of this intervention are of doubtful clinical significance in this condition, a conclusion
unchanged at this update.
Although the authorship of this updated review does not fully comply with the current Conflict of Interests policy, it did at the time
of original publication. This has been discussed with the Funding Arbiters who have agreed that there is a low risk of significant bias
resulting from the declared financial and academic interests.
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External sources
• Patrick Berthoud Charitable Trust, UK.
• Brain Neurology Entry Scholarship, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the 2012 and 2016 updates, both review authors extracted data independently and cross-checked data.
We have added a further outcome measure, but no trials have used this.
In the 2012 update, we included a ’Summary of findings’ table and updated the ’Risk of bias’ methodology.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Demyelinating Diseases [immunology; ∗therapy]; Immunoglobulin M [blood; ∗immunology]; Immunoglobulins, Intravenous
[therapeutic use]; Immunosuppressive Agents [therapeutic use]; Immunotherapy [∗methods]; Myelin-Associated Glycoprotein
[∗immunology]; Paraproteinemias [immunology; ∗therapy]; Paraproteins [immunology]; Peripheral Nervous System Diseases [im-
munology; ∗therapy]; Plasma Exchange [methods]; Randomized Controlled Trials as Topic; Rituximab [therapeutic use]
MeSH check words
Humans
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